MIT Libraries logoDSpace@MIT

MIT
View Item 
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Temporally Programmed CD8α[superscrip +] DC Activation Enhances Combination Cancer Immunotherapy

Author(s)
Szeto, Gregory L.; Overwijk, Willem W.; Tzeng, Alice; Kauke, Monique Jacqueline; Zhu, Eric Franklin; Moynihan, Kelly Dare; Opel, Cary Francis; Yang, Nicole Jie Yeon; Mehta, Naveen; Irvine, Darrell J; Wittrup, Karl Dane; ... Show more Show less
Thumbnail
DownloadTemporally programmed.pdf (1.615Mb)
PUBLISHER_CC

Publisher with Creative Commons License

Creative Commons Attribution

Alternative title
Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy
Terms of use
Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/
Metadata
Show full item record
Abstract
Numerous synergistic cancer immunotherapy combinations have been identified, but the effects of relative dose timing are rarely considered. In established syngeneic mouse tumor models, we found that staggering interferon-α (IFNα) administration after, rather than before or simultaneously with, serum-persistent interleukin-2 (IL-2) and tumor-specific antibody significantly increased long-term survival. Successful combination therapy required IFNα-induced activation of cross-presenting CD8α[superscript +] dendritic cells (DCs) following the release of antigenic tumor debris by the IL-2- and antibody-mediated immune response. Due to decreased phagocytic ability post-maturation, DCs activated too early captured less antigen and could not effectively prime CD8[superscript +] T cells. Temporally programming DC activation to occur after tumoricidal activity enhanced tumor control by multiple distinct combination immunotherapies, highlighting dose schedule as an underappreciated factor that can profoundly affect the success of multi-component immunotherapies.
Date issued
2016-12
URI
http://hdl.handle.net/1721.1/107465
Department
Massachusetts Institute of Technology. Department of Biological Engineering; Massachusetts Institute of Technology. Department of Chemical Engineering; Massachusetts Institute of Technology. Department of Materials Science and Engineering; Koch Institute for Integrative Cancer Research at MIT
Journal
Cell Reports
Publisher
Elsevier
Citation
Tzeng, Alice et al. “Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.” Cell Reports 17.10 (2016): 2503–2511.
Version: Final published version
ISSN
22111247
2211-1247

Collections
  • MIT Open Access Articles

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

Login

Statistics

OA StatisticsStatistics by CountryStatistics by Department
MIT Libraries
PrivacyPermissionsAccessibilityContact us
MIT
Content created by the MIT Libraries, CC BY-NC unless otherwise noted. Notify us about copyright concerns.